NCT06402396Active, not recruiting
Assessing Pain by the painDETECT Questionnaire (PDQ)
Assessing Pain by the painDETECT Questionnaire (PDQ) to Evaluate Drug Retention in Patients With Inflammatory Arthritis: A Danish Nationwide Prospective DANBIO Registry Study
Source: ClinicalTrials.gov · Last updated 20 May 2025
Brief summary (registry, in English)
Prospective cohort study using drug survival rates to assess the predictive value of the PDQ when used to classify patients into a non-neuropathic pain phenotype group (score \<13) or a neuropathic pain phenotype group (score ≥13)
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 7056 (actual)
- First submitted
- 2 May 2024
- Start date
- Jan 2013
- Primary completion date
- 1 Dec 2019
- Lead sponsor
- University Hospital Bispebjerg and Frederiksberg
- Diseases
- Psoriasis, Psoriatic arthritis, Rheumatoid arthritis
- NCT number
- NCT06402396
What you commit to
- Study type: Observational
- Participants enrolled: 7056
- From Jan 2013 to the primary completion date, 1 Dec 2019
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Missing answer to PDQ
Who the study is looking for
- Registered in DANBIO
- Having inflammatory arthritis (Specific diagnoses include RA, PsA and other SpA)
- At time of the PDQ assessment and up to 4 months thereafter being on ongoing bDMARDs treatment or on switch of bDMARD treatment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.